<DOC>
	<DOCNO>NCT00405171</DOCNO>
	<brief_summary>Dyslipidemia coronary heart disease ( CHD ) increasingly recognize person human immunodeficiency virus ( HIV ) infection . Many antiretrovirals , include efavirenz ( EFV ) , associate increase serum lipid . The investigator investigate whether stop EFV replace EFV nevirapine reduce significantly Low-Density Lipoprotein cholesterol , keep virologic control HIV .</brief_summary>
	<brief_title>Efavirenz Nevirapine Switch Low-Density Lipoprotein ( LDL ) -Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infect adult , receive antiretroviral therapy include efavirenz least 6 month plasma HIV RNA &lt; 400 cp/ml previous 4 month 2 occasion 14 day apart Severe dyslipidemia LowDensity Lipoprotein cholesterol ( LDLc ) &gt; 3.4 mmol/L presence least one 3 follow coronary heart disease ( CHD ) risk factor : age &gt; 45 among male age &gt; 55 among female , hypertension , current smoking , family history CHD LowDensity Lipoprotein cholesterol ( LDLc ) &gt; 4.1 mmol/L regardless CHD risk factor . Protease inhibitor use within previous 6 month , Prior exposure nevirapine Asparate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5N hepatitis virus B C negative AST ALT &gt; 1.25N hepatitis virus B C positive Fasting glycemia &gt; 1.26g/L , Current CHD Triglycerides &gt; 4.6 mmol/L Introduction lipid lower drug , corticoïds , retinoïds betablockers within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Efavirenz</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>HIV</keyword>
</DOC>